Claims
- 1. A triazole compound having the formula: ##STR300## wherein Ar.sup.1 represents an unsubstituted phenyl group or a phenyl group having 1 to 3 substituents selected from the group consisting of a halogen atom and a trifluoromethyl group;
- Ar.sup.2 represents an unsubstituted phenyl group or a phenyl group having 1 to 3 substituents selected from the group consisting of an unsubstituted lower alkyl group, an unsubstituted lower alkoxy group, a halogen atom, a halo substituted lower alkyl group, a halo substituted lower alkoxy group, a nitro group, a cyano group, a --S(O).sub.m R.sup.6 group, wherein R.sup.6 represents an unsubstituted lower alkyl group or a halo substituted lower alkyl group and m represents 0, 1 or 2, or a --NHCOR.sup.7 group, wherein R.sup.7 represents a lower alkyl group;
- R.sup.0 represents a hydrogen atom or a lower alkyl group;
- R.sup.1 represents a lower alkyl group;
- R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen atom, an unsubstituted lower alkyl group or a halo substituted lower alkyl group and, where q and/or s represent 2, each of R.sup.2, R.sup.3, R.sup.4 and R.sup.5 represents independently a group which is the same or different from the other R.sup.2, R.sup.3, R.sup.4 and R.sup.5 respectively;
- n represents 0, 1 or 2;
- p represents 0 or 1;
- q, r and s represent 0, 1 or 2; and
- A represents a 1,3-dioxan-5-yl group;
- or a pharmacologically acceptable salt thereof.
- 2. The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein Ar.sup.1 is a phenyl group having 1 or 2 substituents selected from the group consisting of a halogen atom and a trifluoromethyl group.
- 3. The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein Ar.sup.1 is a phenyl group having 1 or 2 substituents selected from the group consisting of a fluorine atom, a chlorine atom and a trifluoromethyl group.
- 4. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1 2, or 3, wherein Ar.sup.2 represents a phenyl group having 1 to 3 substituents selected from the group consisting of an unsubstituted lower alkyl group, a halogen atom, a halo substituted lower alkyl group, a halo substituted lower alkoxy group, a nitro group, a cyano group or a --S(O).sub.m R.sup.6 group, wherein R.sup.6 represents an unsubstituted or halo substituted lower alkyl group and m represents 0, 1 or 2.
- 5. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1 2, or 3, wherein Ar.sup.2 represents an unsubstituted phenyl group.
- 6. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1 2, or 3, wherein Ar.sup.2 represents a phenyl group having 1 or 2 substituents selected from the group consisting of an unsubstituted lower alkyl group, a halogen atom, a halo substituted lower alkyl group, a halo substituted lower alkoxy group, a nitro group, a cyano group or a --S(O).sub.m R.sup.6 group, wherein R.sup.6 represents an unsubstituted or halo substituted lower alkyl group and m represents 0, 1 or 2.
- 7. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein R.sup.0 is a hydrogen atom, a methyl group, an ethyl group or a propyl group.
- 8. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein R.sup.0 is a hydrogen atom, a methyl group or an ethyl group.
- 9. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein R.sup.0 is a hydrogen atom or a methyl group.
- 10. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein R.sup.1 is a methyl group, an ethyl group or a propyl group.
- 11. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein R.sup.1 is a methyl group or an ethyl group.
- 12. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein R.sup.1 is a methyl group.
- 13. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen atom, an unsubstituted lower alkyl group or a fluorine or chlorine substituted lower alkyl group.
- 14. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen atom, an unsubstituted methyl group, an unsubstituted ethyl group, an unsubstituted propyl group, a fluorine or chlorine substituted methyl group, a fluorine or chlorine substituted ethyl group or a fluorine or chlorine substituted propyl group.
- 15. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen atom, an unsubstituted methyl group, an unsubstituted ethyl group, a fluorine or chlorine substituted methyl group or a fluorine or chlorine substituted ethyl group.
- 16. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen atom, an unsubstituted methyl group or a fluorine or chlorine substituted methyl group.
- 17. The triazole compound or a pharmacologically acceptable salt thereof according to claims 2, or 3, wherein n is 0 or 1.
- 18. The triazole compound or a pharmacologically acceptable salt thereof according to claims 1, 2 or 3, wherein n is 0.
- 19. The triazole compound or a pharmacologically acceptable salt thereof according to claims 2 or 3, wherein p is 0.
- 20. The triazole compound or a pharmacologically acceptable salt thereof according to claims 2 or 3, wherein q, r and s are each 0 or 1.
- 21. The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein
- Ar.sup.1 is a phenyl group having 1 to 3 substituents selected from the group consisting of a halogen atom and a trifluoromethyl group;
- R.sup.0 is a hydrogen atom, a methyl group, an ethyl group or a propyl group;
- R.sup.1 is a methyl group, an ethyl group or a propyl group;
- R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are independently selected from the group consisting of a hydrogen atom, an unsubstituted lower alkyl group and a fluorine or chlorine substituted lower alkyl group.
- 22. The triazole compound or a pharmacologically acceptable salt thereof according to claim 1, wherein
- R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and are a hydrogen atom, unsubstituted methyl group, an unsubstituted ethyl group, an unsubstituted propyl group, a fluorine or chlorine substituted methyl group, a fluorine or chlorine substituted ethyl group or a fluorine or chlorine substituted propyl group.
- 23. The triazole compound or a pharmacologically acceptable salt thereof according to claim 22, wherein R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and are a hydrogen atom, an unsubstituted methyl group or a fluorine or chlorine substituted methyl group;
- n is 0.
- 24. The triazole compound or a pharmacologically acceptable salt according to claim 23, wherein
- R.sup.0 is a hydrogen atom or a methyl group;
- R.sup.1 is methyl; and
- Ar.sup.1 is a phenyl group having 1 or 2 substituents independently selected from the group consisting of fluorine, chlorine and trifluoromethyl.
- 25. An antifungal composition comprising an antifungally effective amount of a triazole compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or diluent.
- 26. A triazole compound which is selected from the group consisting of 2-(2,4-difluorophenyl)-3-[[2-[2-[4-(trifluoromethyl)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-1-(1H-1,2,4-triazol-1-yl)-2-butanol,
- 2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-[[2-[2-[4-(trifluoromethoxy)phenyl]vinyl]-1,3-dioxan-5-yl]thio]-2-butanol,
- 2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
- 2-(2,4-difluorophenyl)-3-[[2-[4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1H-1,2,4-triazol-1-yl)-2-butanol,
- 2-(2,4-difluorophenyl)-3-[[2-[4-(4-(chlorophenyl)-5,5,5-trifluoro-1,3-pentadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1H-1,2,4-triazol-1-yl)-2-butanol,
- 3-methyl-1-(1H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-3-[[2-[4(trifluoromethyl)phenyl)-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
- 2-(2,4-diflurophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-[[2-[4-(trifluoromethylthio)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
- 3-[[2-[4-[4-(2,2,3,3,-tetrafluoropropoxy)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-1-(1H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl)-2-butanol,
- 1-(1H-1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
- 2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluromethylsulfinyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
- 2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-[[2-[6-[4-(trifluoromethyl)phenyl]-1,3,5-hexatrien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
- 2-(2,4-difluorophenyl)-3-methyl-1-(1H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1,3-butadien-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol and
- 2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-[[2-[4-[4-(trifluoromethyl)phenyl]-1-buten-3-yn-1-yl]-1,3-dioxan-5-yl]thio]-2-butanol,
- or a pharmacologically acceptable salt thereof.
- 27. A method of treating a patient suffering from a fungal infection comprising administering to the patient an effective fungicidal amount of the compound of claim 1 or a pharmacologically acceptable salt thereof.
- 28. An antifungal composition comprising an antifungally effective amount of a triazole compound of claim 26 or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or diluent.
Priority Claims (1)
Number |
Date |
Country |
Kind |
7-081052 |
Apr 1995 |
JPX |
|
Parent Case Info
This application is a continuation-in-part application of International application PCT/JP96/00932 filed Apr. 5, 1996, now abandoned, which is hereby incorporated in its entirety.
US Referenced Citations (10)
Foreign Referenced Citations (9)
Number |
Date |
Country |
0 140 154 |
May 1985 |
EPX |
0 150 036 |
Jul 1985 |
EPX |
178533 |
Apr 1986 |
EPX |
180136 |
May 1986 |
EPX |
0 332 387 |
Sep 1989 |
EPX |
421210 |
Apr 1991 |
EPX |
473387 |
Mar 1992 |
EPX |
510700 |
Oct 1992 |
EPX |
6-247944 |
Sep 1994 |
JPX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCTJP9600932 |
Apr 1996 |
|